Section 17 - Novel Cell Therapies and Manipulations: Ready for Prime-Time?

Sadelain, M, Brentjens, R, Riviere, I. The basic principles of chimeric antigen receptor design. Cancer Discovery. 2013;3(4):388–98. PubMed PMID: 23550147. Pubmed Central PMCID: PMC3667586.CrossRefGoogle ScholarPubMed

Dao, T, Yan, S, Veomett, N, Pankov, D, Zhou, L, Korontsvit, T, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science Translational Medicine. 2013;5(176):176ra33. PubMed PMID: 23486779. Pubmed Central PMCID: PMC3963696.CrossRefGoogle ScholarPubMed

Hudecek, M, Lupo-Stanghellini, MT, Kosasih, PL, Sommermeyer, D, Jensen, MC, Rader, C, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2013;19(12):3153–64. PubMed PMID: 23620405. Pubmed Central PMCID: PMC3804130.CrossRefGoogle ScholarPubMed

Eshhar, Z, Waks, T, Gross, G, Schindler, DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(2):720–4. PubMed PMID: 8421711. Pubmed Central PMCID: PMC45737.CrossRefGoogle ScholarPubMed

Brocker, T, Karjalainen, K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. The Journal of Experimental Medicine. 1995;181(5):1653–9. PubMed PMID: 7722445. Pubmed Central PMCID: PMC2192006.CrossRefGoogle ScholarPubMed

Gong, MC, Latouche, JB, Krause, A, Heston, WD, Bander, NH, Sadelain, M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia. 1999;1(2):123–7. PubMed PMID: 10933046. Pubmed Central PMCID: PMC1508130.CrossRefGoogle ScholarPubMed

Maher, J, Brentjens, RJ, Gunset, G, Riviere, I, Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nature Biotechnology. 2002;20(1):70–5. PubMed PMID: 11753365.CrossRefGoogle ScholarPubMed

Brentjens, RJ, Latouche, JB, Santos, E, Marti, F, Gong, MC, Lyddane, C, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Medicine. 2003;9(3):279–86. PubMed PMID: 12579196.CrossRefGoogle Scholar

Kowolik, CM, Topp, MS, Gonzalez, S, Pfeiffer, T, Olivares, S, Gonzalez, N, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Research. 2006;66(22):10995–1004. PubMed PMID: 17108138.CrossRefGoogle ScholarPubMed

Finney, HM, Akbar, AN, Lawson, AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. Journal of Immunology. 2004;172(1):104–13. PubMed PMID: 14688315.CrossRefGoogle ScholarPubMed

Hombach, A, Sent, D, Schneider, C, Heuser, C, Koch, D, Pohl, C, et al. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Research. 2001;61(5):1976–82. PubMed PMID: 11280755.Google Scholar

Savoldo, B, Ramos, CA, Liu, E, Mims, MP, Keating, MJ, Carrum, G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. The Journal of Clinical Investigation. 2011;121(5):1822–6. PubMed PMID: 21540550. Pubmed Central PMCID: PMC3083795.CrossRefGoogle ScholarPubMed

Carpenito, C, Milone, MC, Hassan, R, Simonet, JC, Lakhal, M, Suhoski, MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(9):3360–5. PubMed PMID: 19211796. Pubmed Central PMCID: PMC2651342.CrossRefGoogle Scholar

Davila, ML, Riviere, I, Wang, X, Bartido, S, Park, J, Curran, K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine. 2014;6(224):224ra25. PubMed PMID: 24553386.CrossRefGoogle Scholar

Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. The New England Journal of Medicine. 2013;368(16):1509–18. PubMed PMID: 23527958. Pubmed Central PMCID: PMC4058440.CrossRefGoogle ScholarPubMed

Jackson, HJ, Rafiq, S, Brentjens, RJ. Driving CAR T cells forward. Nature Reviews Clinical Oncology. 2016;13:370–83.CrossRefGoogle Scholar

Zhong, XS, Matsushita, M, Plotkin, J, Riviere, I, Sadelain, M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Molecular Therapy: The Journal of the American Society of Gene Therapy. 2010;18(2):413–20. PubMed PMID: 19773745. Pubmed Central PMCID: PMC2839303.CrossRefGoogle Scholar

Tammana, S, Huang, X, Wong, M, Milone, MC, Ma, L, Levine, BL, et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Human Gene Therapy. 2010;21(1):75–86. PubMed PMID: 19719389. Pubmed Central PMCID: PMC2861957.CrossRefGoogle Scholar

Wang, J, Jensen, M, Lin, Y, Sui, X, Chen, E, Lindgren, CG, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Human Gene Therapy. 2007;18(8):712–25. PubMed PMID: 17685852.CrossRefGoogle ScholarPubMed

Brentjens, RJ, Riviere, I, Park, JH, Davila, ML, Wang, X, Stefanski, J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817–28. PubMed PMID: 21849486. Pubmed Central PMCID: PMC3208293.CrossRefGoogle ScholarPubMed

Brentjens, RJ, Davila, ML, Riviere, I, Park, J, Wang, X, Cowell, LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science Translational Medicine. 2013;5(177):177ra38. PubMed PMID: 23515080. Pubmed Central PMCID: PMC3742551.CrossRefGoogle ScholarPubMed

Lee, DW, Kochenderfer, JN, Stetler-Stevenson, M, Cui, YK, Delbrook, C, Feldman, SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967): 517–28.CrossRefGoogle Scholar

Turtle, CJ, Hanafi, LA, Berger, C, Gooley, TA, Cherian, S, Hudecek, M, et al. CD19 CAR–T cells of defined CD4+ : CD8+ composition in adult B cell ALL patients. Journal of Clinical Investigation. 2016;126(6).CrossRefGoogle ScholarPubMed

Porter, DL, Levine, BL, Kalos, M, Bagg, A, June, CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Journal of Medicine. 2011;365(8):725–33. PubMed PMID: 21830940. Pubmed Central PMCID: PMC3387277.CrossRefGoogle ScholarPubMed

Porter, DL, Hwang, WT, Frey, NV, Lacey, SF, Shaw, PA, Loren, AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine. 2015;7(303):303–39.CrossRefGoogle ScholarPubMed

Kochenderfer, JN, Wilson, WH, Janik, JE, Dudley, ME, Stetler-Stevenson, M, Feldman, SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T-cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099–102. PubMed PMID: 20668228. Pubmed Central PMCID: PMC2993617.CrossRefGoogle Scholar

Kochenderfer, JN, Dudley, ME, Feldman, SA, Wilson, WH, Spaner, DE, Maric, I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–20. PubMed PMID: 22160384. Pubmed Central PMCID: PMC3327450.CrossRefGoogle Scholar

Kochenderfer, JN, Dudley, ME, Kassim, SH, Somerville, RP, Carpenter, RO, Stetler-Stevenson, M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T-cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2015;33(6): 540–9. PubMed PMID: 25154820.CrossRefGoogle ScholarPubMed

Turtle, , et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells. Science Translational Medicine. 2016;8(355).CrossRefGoogle ScholarPubMed

Till, BG, Jensen, MC, Wang, J, Chen, EY, Wood, BL, Greisman, HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T-cells. Blood. 2008;112(6):2261–71. PubMed PMID: 18509084. Pubmed Central PMCID: PMC2532803.CrossRefGoogle ScholarPubMed

Till, BG, Jensen, MC, Wang, J, Qian, X, Gopal, AK, Maloney, DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119(17):3940–50. PubMed PMID: 22308288. Pubmed Central PMCID: PMC3350361.CrossRefGoogle ScholarPubMed

Burger, JA, Ghia, P, Rosenwald, A, Caligaris-Cappio, F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367–75. PubMed PMID: 19636060.CrossRefGoogle ScholarPubMed

Herishanu, Y, Perez-Galan, P, Liu, D, Biancotto, A, Pittaluga, S, Vire, B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563–74. PubMed PMID: 20940416. Pubmed Central PMCID: PMC3031480.CrossRefGoogle ScholarPubMed

Christopoulos, P, Pfeifer, D, Bartholome, K, Follo, M, Timmer, J, Fisch, P, et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood. 2011;117(14):3836–46. PubMed PMID: 21270444.CrossRefGoogle ScholarPubMed

Riches, JC, Davies, JK, McClanahan, F, Fatah, R, Iqbal, S, Agrawal, S, et al. T-cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612–21. PubMed PMID: 23247726. Pubmed Central PMCID: PMC3587324.CrossRefGoogle ScholarPubMed

Davila, ML, Bouhassira, DC, Park, JH, Curran, KJ, Smith, EL, Pegram, HJ, et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. International Journal of Hematology. 2014;99(4):361–71. PubMed PMID: 24311149.CrossRefGoogle ScholarPubMed

Neeson, P, Shin, A, Tainton, KM, Guru, P, Prince, HM, Harrison, SJ, et al. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T-cells with effector and central memory-like phenotype. Gene Therapy. 2010;17(9):1105–16. PubMed PMID: 20428216.CrossRefGoogle Scholar

Ali, SA, Shi, V, Maric, I, Wang, M, Stroncek, DF, Rose, JJ, et al. T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688–700.CrossRefGoogle Scholar

Ritchie, DS, Neeson, PJ, Khot, A, Peinert, S, Tai, T, Tainton, K, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Molecular Therapy: The Journal of the American Society of Gene Therapy. 2013;21(11):2122–9. PubMed PMID: 23831595. Pubmed Central PMCID: PMC3831035.CrossRefGoogle Scholar

Gajewski, TF, Schreiber, H, Fu, YX. Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology. 2013;14(10):1014–22. PubMed PMID: 24048123. Pubmed Central PMCID: PMC4118725.CrossRefGoogle ScholarPubMed

Lee, JC, Hayman, E, Pegram, HJ, Santos, E, Heller, G, Sadelain, M, et al. In vivo inhibition of human CD19-targeted effector T-cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Research. 2011;71(8):2871–81. PubMed PMID: 21487038. Pubmed Central PMCID: PMC3094720.Google Scholar

Kershaw, MH, Westwood, JA, Parker, LL, Wang, G, Eshhar, Z, Mavroukakis, SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2006;12(20 Pt 1):6106–15. PubMed PMID: 17062687. Pubmed Central PMCID: PMC2154351.CrossRefGoogle ScholarPubMed

Louis, CU, Savoldo, B, Dotti, G, Pule, M, Yvon, E, Myers, GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T-cells in patients with neuroblastoma. Blood. 2011;118(23):6050–6. PubMed PMID: 21984804. Pubmed Central PMCID: PMC3234664.CrossRefGoogle ScholarPubMed

Maus, MV, Haas, AR, Beatty, GL, Albelda, SM, Levine, BL, Liu, X, et al. T-cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunology Research. 2013;1(1):26–31. PubMed PMID: 24777247.CrossRefGoogle Scholar

Hegde, M, Corder, A, Chow, KK, Mukherjee, M, Ashoori, A, Kew, Y, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Molecular Therapy: The Journal of the American Society of Gene Therapy. 2013;21(11):2087–101. PubMed PMID: 23939024. Pubmed Central PMCID: PMC3831041.CrossRefGoogle Scholar

Duong, CP, Westwood, JA, Berry, LJ, Darcy, PK, Kershaw, MH. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy. 2011;3(1):33–48. PubMed PMID: 21174556.CrossRefGoogle ScholarPubMed

Kloss, CC, Condomines, M, Cartellieri, M, Bachmann, M, Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T-cells. Nature Biotechnology. 2013;31(1):71–5. PubMed PMID: 23242161.Google ScholarPubMed

Kakarla, S, Chow, K, Mata, M, Shaffer, DR, Song, XT, Wu, MF, et al. Antitumor effects of chimeric receptor engineered human T-cells directed to tumor stroma. Molecular Therapy: The Journal of the American Society of Gene Therapy. 2013;21(8):1611–20. PubMed PMID: 23732988. Pubmed Central PMCID: PMC3734659.CrossRefGoogle ScholarPubMed

Chmielewski, M, Hombach, AA, Abken, H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunological Reviews. 2014;257(1):83–90. PubMed PMID: 24329791.CrossRefGoogle ScholarPubMed

Pegram, HJ, Lee, JC, Hayman, EG, Imperato, GH, Tedder, TF, Sadelain, M, et al. Tumor-targeted T-cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119(18):4133–41. PubMed PMID: 22354001. Pubmed Central PMCID: PMC3359735.CrossRefGoogle Scholar

Leonard, JP, Sherman, ML, Fisher, GL, Buchanan, LJ, Larsen, G, Atkins, MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90(7):2541–8. PubMed PMID: 9326219.Google Scholar

Koneru, M, O’Cearbhaill, R, Pendharkar, S, Spriggs, DR, Brentjens, RJ. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer. Journal of Translational Medicine. 2015;13:102.CrossRefGoogle ScholarPubMed

Stephan, MT, Ponomarev, V, Brentjens, RJ, Chang, AH, Dobrenkov, KV, Heller, G, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature Medicine. 2007;13(12):1440–9. PubMed PMID: 18026115.CrossRefGoogle Scholar

Davila, ML, Kloss, CC, Gunset, G, Sadelain, M. CD19 CAR-targeted T-cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS one. 2013;8(4):e61338. PubMed PMID: 23585892. Pubmed Central PMCID: PMC3621858.CrossRefGoogle Scholar

Morgan, RA, Yang, JC, Kitano, M, Dudley, ME, Laurencot, CM, Rosenberg, SA. Case report of a serious adverse event following the administration of T-cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy: The Journal of the American Society of Gene Therapy. 2010;18(4):843–51. PubMed PMID: 20179677. Pubmed Central PMCID: PMC2862534.CrossRefGoogle ScholarPubMed

Di Stasi, A, Tey, SK, Dotti, G, Fujita, Y, Kennedy-Nasser, A, Martinez, C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. The New England Journal of Medicine. 2011;365(18):1673–83. PubMed PMID: 22047558. Pubmed Central PMCID: PMC3236370.CrossRefGoogle ScholarPubMed

Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine. 2011;3(95):95ra73. PubMed PMID: 21832238. Pubmed Central PMCID: PMC3393096.CrossRefGoogle ScholarPubMed

Teachey, DT, Lacey, SF, Shaw, PA, Melenhorst, J, Maude, SL, Frey, N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discovery. 2016; 10.1158/2159–8290.CD-16-0040.Google Scholar

Bonifant, CL, Jackson, HJ, Brentjens, RJ, Curran, KJ. Toxicity and management in CAR T-cell therapy. Molecular Therapy: Oncolytics. 2016;3:16011; doi:10.1038/mto.2016.11.Google ScholarPubMed

Raulet, DH, Guerra, N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol. 2009;9(8):568–80. Epub 2009/07/25.CrossRefGoogle ScholarPubMed

Almeida-Oliveira, A, Smith-Carvalho, M, Porto, LC, Cardoso-Oliveira, J, Ribeiro Ados, S, Falcao, RR, et al. Age-related changes in natural killer cell receptors from childhood through old age. Hum Immunol. 2011;72(4):319–29. Epub 2011/01/26.CrossRefGoogle ScholarPubMed

Kiessling, R, Klein, E, Wigzell, H. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5(2):112–7. Epub 1975/02/01.Google ScholarPubMed

Herberman, RB, Nunn, ME, Lavrin, DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer. 1975;16(2):216–29. Epub 1975/08/15.Google ScholarPubMed

Murphy, WJ, Koh, CY, Raziuddin, A, Bennett, M, Longo, DL. Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies. Immunol Rev. 2001;181:279–89. Epub 2001/08/22.CrossRefGoogle ScholarPubMed

Ljunggren, HG, Karre, K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237–44.CrossRefGoogle ScholarPubMed

Raulet, DH, Correa, I, Corral, L, Dorfman, J, Wu, MF. Inhibitory effects of class I molecules on murine NK cells: speculations on function, specificity and self-tolerance. Semi Immunol. 1995;7(2):103–7. Epub 1995/04/01.Google Scholar

Farag, SS, Caligiuri, MA. Human natural killer cell development and biology. Blood Rev. 2006;20(3):123–37. Epub 2005/12/21.CrossRefGoogle ScholarPubMed

Uhrberg, M, Valiante, NM, Shum, BP, Shilling, HG, Lienert-Weidenbach, K, Corliss, B, et al. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7(6):753–63. Epub 1998/01/16.CrossRefGoogle ScholarPubMed

Zhao, XY, Chang, YJ, Xu, LP, Zhang, XH, Liu, KY, Li, D, et al. HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients. Br J Cancer. 2014;111(6):1080–8. Epub 2014/08/01.CrossRefGoogle Scholar

Shilling, HG, McQueen, KL, Cheng, NW, Shizuru, JA, Negrin, RS, Parham, P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood. 2003;101(9):3730–40. Epub 2003/01/04.CrossRefGoogle ScholarPubMed

Giebel, S, Dziaczkowska, J, Czerw, T, Wojnar, J, Krawczyk-Kulis, M, Nowak, I, et al. Sequential recovery of NK cell receptor repertoire after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2010;45(6):1022–30. Epub 2010/02/02.CrossRefGoogle ScholarPubMed

Beziat, V, Liu, LL, Malmberg, JA, Ivarsson, MA, Sohlberg, E, Bjorklund, AT, et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood. 2013;121(14):2678–88. Epub 2013/01/18.CrossRefGoogle ScholarPubMed

Foley, B, Cooley, S, Verneris, MR, Pitt, M, Curtsinger, J, Luo, X, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood. 2012;119(11):2665–74. Epub 2011/12/20.CrossRefGoogle ScholarPubMed

Foley, B, Cooley, S, Verneris, MR, Curtsinger, J, Luo, X, Waller, EK, et al. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol. 2012;189(10):5082–8. Epub 2012/10/19.CrossRefGoogle Scholar

Ruggeri, L, Mancusi, A, Capanni, M, Urbani, E, Carotti, A, Aloisi, T, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110(1):433–40. Epub 2007/03/21.CrossRefGoogle Scholar

Symons, HJ, Leffell, MS, Rossiter, ND, Zahurak, M, Jones, RJ, Fuchs, EJ. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2010;16(4):533–42. Epub 2009/12/08.CrossRefGoogle ScholarPubMed

Brunstein, CG, Wagner, JE, Weisdorf, DJ, Cooley, S, Noreen, H, Barker, JN, et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood. 2009;113(22):5628–34. Epub 2009/03/31.CrossRefGoogle ScholarPubMed

Miller, JS, Cooley, S, Parham, P, Farag, SS, Verneris, MR, McQueen, KL, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109(11):5058–61.CrossRefGoogle ScholarPubMed

Horowitz, A, Strauss-Albee, DM, Leipold, M, Kubo, J, Nemat-Gorgani, N, Dogan, OC, et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med. 2013;5(208):208ra145. Epub 2013/10/25.CrossRefGoogle ScholarPubMed

Bertaina, A, Merli, P, Rutella, S, Pagliara, D, Bernardo, ME, Masetti, R, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders. Blood. 2014;124(5):822–6. Epub 2014/05/30.CrossRefGoogle Scholar

Kanakry, CG, O’Donnell, PV, Furlong, T, de Lima, MJ, Wei, W, Medeot, M, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014;32(31):3497–505. Epub 2014/10/01.CrossRefGoogle ScholarPubMed

Derniame, S, Perazzo, J, Lee, F, Domogala, A, Escobedo-Cousin, M, Alnabhan, R, et al. Differential effects of mycophenolate mofetil and cyclosporine A on peripheral blood and cord blood natural killer cells activated with interleukin-2. Cytotherapy. 2014;16(10):1409–18.CrossRefGoogle ScholarPubMed

Rubnitz, JE, Inaba, H, Ribeiro, RC, Pounds, S, Rooney, B, Bell, T, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955–9. Epub 2010/01/21.CrossRefGoogle ScholarPubMed

Choi, I, Yoon, SR, Park, SY, Kim, H, Jung, SJ, Jang, YJ, et al. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant. 2014;20(5):696–704. Epub 2014/02/15.CrossRefGoogle ScholarPubMed

Shah, NN, Baird, K, Delbrook, CP, Fleisher, TA, Kohler, ME, Rampertaap, S, et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T cell depleted stem cell transplantation. Blood. 2015;125(5):784–92.CrossRefGoogle ScholarPubMed

Fujisaki, H, Kakuda, H, Shimasaki, N, Imai, C, Ma, J, Lockey, T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69(9):4010–7. Epub 2009/04/23.CrossRefGoogle Scholar

Denman, CJ, Senyukov, VV, Somanchi, SS, Phatarpekar, PV, Kopp, LM, Johnson, JL, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012;7(1):e30264. Epub 2012/01/27.CrossRefGoogle ScholarPubMed

Spanholtz, J, Preijers, F, Tordoir, M, Trilsbeek, C, Paardekooper, J, de Witte, T, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One. 2011;6(6):e20740. Epub 2011/06/24.CrossRefGoogle ScholarPubMed

Berg, M, Lundqvist, A, McCoy, P Jr., Samsel, L, Fan, Y, Tawab, A, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11(3):341–55. Epub 2009/03/25.CrossRefGoogle ScholarPubMed

Ruggeri, L, Capanni, M, Urbani, E, Perruccio, K, Shlomchik, WD, Tosti, A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–100.CrossRefGoogle ScholarPubMed

Giebel, S, Locatelli, F, Lamparelli, T, Velardi, A, Davies, S, Frumento, G, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3):814–9.CrossRefGoogle ScholarPubMed

Beelen, DW, Ottinger, HD, Ferencik, S, Elmaagacli, AH, Peceny, R, Trenschel, R, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood. 2005;105(6):2594–600. Epub 2004/11/13.CrossRefGoogle ScholarPubMed

Elmaagacli, AH, Ottinger, H, Koldehoff, M, Peceny, R, Steckel, NK, Trenschel, R, et al. Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Transplantation. 2005;79(12):1741–7. Epub 2005/06/24.CrossRefGoogle ScholarPubMed

Lang, P, Pfeiffer, M, Teltschik, HM, Schlegel, P, Feuchtinger, T, Ebinger, M, et al. Natural killer cell activity influences outcome after T cell depleted stem cell transplantation from matched unrelated and haploidentical donors. Best Pract Res Clin Haematol. 2011;24(3):403–11. Epub 2011/09/20.CrossRefGoogle Scholar

Oevermann, L, Michaelis, SU, Mezger, M, Lang, P, Toporski, J, Bertaina, A, et al. KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood. 2014;124(17):2744–7. Epub 2014/08/15.CrossRefGoogle Scholar

Michaelis, SU, Mezger, M, Bornhauser, M, Trenschel, R, Stuhler, G, Federmann, B, et al. KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts. Ann Hematol. 2014;93(9):1579–86. Epub 2014/04/29.CrossRefGoogle ScholarPubMed

Yamasaki, S, Henzan, H, Ohno, Y, Yamanaka, T, Iino, T, Itou, Y, et al. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone Marrow Transplant. 2003;32(5):505–10. Epub 2003/08/28.CrossRefGoogle ScholarPubMed

Verheyden, S, Schots, R, Duquet, W, Demanet, C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia. 2005;19(8):1446–51. Epub 2005/06/24.Google ScholarPubMed

Hsu, KC, Keever-Taylor, CA, Wilton, A, Pinto, C, Heller, G, Arkun, K, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105(12):4878–84.CrossRefGoogle ScholarPubMed

Kim, DH, Sohn, SK, Lee, NY, Baek, JH, Kim, JG, Won, DI, et al. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors. Eur J Haematol. 2005;75(4):299–308. Epub 2005/09/09.CrossRefGoogle ScholarPubMed

Hsu, KC, Gooley, T, Malkki, M, Pinto-Agnello, C, Dupont, B, Bignon, JD, et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2006;12(8):828–36. Epub 2006/07/26.CrossRefGoogle Scholar

Savani, BN, Mielke, S, Adams, S, Uribe, M, Rezvani, K, Yong, AS, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia. 2007;21(10):2145–52. Epub 2007/08/04.Google Scholar

Willemze, R, Rodrigues, CA, Labopin, M, Sanz, G, Michel, G, Socie, G, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia. 2009;23(3):492–500. Epub 2009/01/20.CrossRefGoogle ScholarPubMed

Cooley, S, Trachtenberg, E, Bergemann, TL, Saeteurn, K, Klein, J, Le, CT, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113(3):726–32. Epub 2008/10/24.CrossRefGoogle Scholar

Cooley, S, Weisdorf, DJ, Guethlein, LA, Klein, JP, Wang, T, Le, CT, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411–9. Epub 2010/06/29.CrossRefGoogle ScholarPubMed

Tomblyn, M, Young, JA, Haagenson, MD, Klein, JP, Trachtenberg, EA, Storek, J, et al. Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype. Biol Blood Marrow Transplant. 2010;16(8):1155–61. Epub 2010/03/04.CrossRefGoogle ScholarPubMed

Yamamoto, W, Ogusa, E, Matsumoto, K, Maruta, A, Ishigatsubo, Y, Kanamori, H. Recovery of natural killer cells and prognosis after cord blood transplantation. Leuk Res. 2013;37(11):1522–6. Epub 2013/10/08.CrossRefGoogle ScholarPubMed

Leung, W, Handgretinger, R, Iyengar, R, Turner, V, Holladay, MS, Hale, GA. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer. 2007;97(4):539–42. Epub 2007/08/02.CrossRefGoogle Scholar

Venstrom, JM, Zheng, J, Noor, N, Danis, KE, Yeh, AW, Cheung, IY, et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res. 2009;15(23):7330–4. Epub 2009/11/26.CrossRefGoogle ScholarPubMed

Boeckh, M, Leisenring, W, Riddell, SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T cell immunity. Blood. 2003;101(2):407–414.CrossRefGoogle ScholarPubMed

Brunstein, CG, Weisdorf, DJ, DeFor, T, et al. Marked increased risk of Epstein–Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006;108(8):2874–2880.CrossRefGoogle ScholarPubMed

Myers, GD, Krance, RA, Weiss, H, et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005;36(11):1001–1008.CrossRefGoogle Scholar

Neofytos, D, Horn, D, Anaissie, E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265–273.CrossRefGoogle ScholarPubMed

Avery, R. Update in management of Ganciclovir-resistant cytomegalovirus infection. Curr Opin Infect Dis. 2008;21:433–437.CrossRefGoogle ScholarPubMed

Biron, KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006;71(2–3):154–163.CrossRefGoogle ScholarPubMed

Nichols, WG, Corey, L, Gooley, T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001;97(4):867–874.CrossRefGoogle ScholarPubMed

Ljungman, P, Deliliers, GL, Platzbecker, U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2001;97(2):388–392.CrossRefGoogle ScholarPubMed

Kuehnle, I, Huls, MH, Liu, Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95(4):1502–1505.Google ScholarPubMed

Papadopoulos, EB, Ladanyi, M, Emanuel, D, et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330(17):1185–1191.CrossRefGoogle ScholarPubMed

Slezak, SL, Bettinotti, M, Selleri, S, Adams, S, Marincola, FM, Stroncek, DF. CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Transl Med. 2007;5:17.CrossRefGoogle ScholarPubMed

Leen, AM, Christin, A, Khalil, M, et al. Identification of hexon-specific CD4 and CD8 T cell epitopes for vaccine and immunotherapy. J Virol. 2008;82(1):546–554.CrossRefGoogle ScholarPubMed

Bollard, CM, Rooney, CM, Heslop, HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012;9(9):510–519.CrossRefGoogle Scholar

Hanley, PJ, Cruz, CR, Savoldo, B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114(9):1958–1967.CrossRefGoogle Scholar

Leen, AM, Myers, GD, Sili, U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160–1166.CrossRefGoogle ScholarPubMed

Sili, U, Huls, MH, Davis, AR, et al. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003;26(3):241–256.CrossRefGoogle Scholar

Kern, F, Faulhaber, N, Frommel, C, et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol. 2000;30(6):1676–1682.3.0.CO;2-V>CrossRefGoogle ScholarPubMed

Hanley, PJ, Shaffer, DR, Cruz, CR, et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein–Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011;13(8):976–986.CrossRefGoogle ScholarPubMed

Kalos, M, June, CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39(1):49–60.CrossRefGoogle ScholarPubMed

Sellar, RS, Peggs, KS. The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation. Cytotherapy. 2012;14(4):391–400.CrossRefGoogle ScholarPubMed

Hansen, SG, Powers, CJ, Richards, R, et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science. 2010;328(5974):102–106.CrossRefGoogle ScholarPubMed

Neudorfer, J, Schmidt, B, Huster, KM, et al. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods. 2007;320(1–2):119–131.CrossRefGoogle Scholar

Schmitt, A, Tonn, T, Busch, DH, et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion. 2011;51(3):591–599.CrossRefGoogle ScholarPubMed

Bollard, CM, Kuehnle, I, Leen, A, Rooney, CM, Heslop, HE. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004;10(3):143–155.CrossRefGoogle ScholarPubMed

Gattinoni, L, Klebanoff, CA, Palmer, DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T-cells. J Clin Invest. 2005;115(6):1616–1626.CrossRefGoogle ScholarPubMed

Heslop, HE, Slobod, KS, Pule, MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–935.CrossRefGoogle ScholarPubMed

Melenhorst, JJ, Leen, AM, Bollard, CM, et al. Allogeneic virus-specific T-cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116(22):4700–4702.CrossRefGoogle Scholar

Peggs, KS, Verfuerth, S, Pizzey, A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. The Lancet. 2003;362(9393):1375–1377.CrossRefGoogle ScholarPubMed

Rooney, CM, Smith, CA, Ng, CY, et al. Infusion of cytotoxic T-cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92(5):1549–1555.Google ScholarPubMed

Walter, EA, Greenberg, PD, Gilbert, MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333(16):1038–1044.CrossRefGoogle Scholar

Trivedi, D, Williams, RY, O’Reilly, RJ, Koehne, G. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood. 2005;105(7):2793–2801.CrossRefGoogle ScholarPubMed

Gerdemann, U, Keirnan, JM, Katari, UL, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012;20(8):1622–1632.CrossRefGoogle ScholarPubMed

Hanley, PJC, Melenhorst, J, Scheinberg, P, et al. Naïve T-cell-derived CTL recognize atypical epitopes of CMVpp65 with higher avidity than CMV-seropositive donor-derived CTL – a basis for treatment of post-transplant viral infection by adoptive transfer of T-cells from virus-naïve donors. ISCT 2013 Annual Meeting (Abstract); 2013.

Berger, C, Jensen, MC, Lansdorp, PM, Gough, M, Elliott, C, Riddell, SR. Adoptive transfer of effector CD8+ T-cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118(1):294–305.CrossRefGoogle ScholarPubMed

Willinger, T, Freeman, T, Hasegawa, H, McMichael, AJ, Callan, MF. Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets. J Immunol. 2005;175(9):5895–5903.CrossRefGoogle ScholarPubMed

Janeway, C. Immunobiology: The Immune System in Health and Disease. 6th ed. New York: Garland Science; 2005.Google Scholar

Leen, AM, Rooney, CM, Foster, AE. Improving T cell therapy for cancer. Ann Rev Immunol. 2007;25:243–265.CrossRefGoogle ScholarPubMed

Eshhar, Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother. 1997;45(3–4):131–136.CrossRefGoogle ScholarPubMed

Schub, A, Schuster, IG, Hammerschmidt, W, Moosmann, A. CMV-specific TCR-transgenic T cells for immunotherapy. J Immunol. 2009;183(10):6819–6830.CrossRefGoogle ScholarPubMed

Scholten, KB, Turksma, AW, Ruizendaal, JJ, et al. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. J Transl Med. 2011;9:147.CrossRefGoogle ScholarPubMed

Gehring, AJ, Xue, SA, Ho, ZZ, et al. Engineering virus-specific T-cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol. 2011;55(1):103–110.CrossRefGoogle ScholarPubMed

Zhang, Y, Liu, Y, Moxley, KM, et al. Transduction of human T-cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathogens. 2010;6(7):e1001018.CrossRefGoogle ScholarPubMed

Luo, W, Zhang, XB, Huang, YT, et al. Development of genetically engineered CD4+ and CD8+ T cells expressing TCRs specific for a M. tuberculosis 38-kDa antigen. J Mol Med (Berl). 2011;89(9):903–913.CrossRefGoogle ScholarPubMed

Oh, HL, Chia, A, Chang, CX, et al. Engineering T-cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope. J Virol. 2011;85(20):10464–10471.CrossRefGoogle ScholarPubMed

Roan, NR, Starnbach, MN. Antigen-specific CD8+ T cells respond to Chlamydia trachomatis in the genital mucosa. J Immunol. 2006;177(11):7974–7979.CrossRefGoogle ScholarPubMed

Ueno, T, Fujiwara, M, Tomiyama, H, Onodera, M, Takiguchi, M. Reconstitution of anti-HIV effector functions of primary human CD8 T lymphocytes by transfer of HIV-specific alphabeta TCR genes. Eur J Immunol. 2004;34(12):3379–3388.CrossRefGoogle ScholarPubMed

Masiero, S, Del Vecchio, C, Gavioli, R, et al. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther. 2005;12(4):299–310.CrossRefGoogle ScholarPubMed

Sahu, GK, Sango, K, Selliah, N, Ma, Q, Skowron, G, Junghans, RP. Anti-HIV designer T-cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology. 2013;446(1–2):268–275.CrossRefGoogle ScholarPubMed

Bitton, N, Verrier, F, Debre, P, Gorochov, G. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120. Eur J immunol. 1998;28(12):4177–4187.3.0.CO;2-J>CrossRefGoogle Scholar

Joseph, A, Zheng, JH, Follenzi, A, et al. Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in-vitro and in vivo HIV-1-specific inhibitory activity. J Virol. 2008;82(6):3078–3089.CrossRefGoogle ScholarPubMed

Kumaresan, PR, Manuri, PR, Albert, ND, et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci USA. 2014;111(29):10660–10665.CrossRefGoogle ScholarPubMed

Cobbold, M, Khan, N, Pourgheysari, B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202(3):379–386.CrossRefGoogle ScholarPubMed

Feuchtinger, T, Opherk, K, Bethge, WA, et al. Adoptive transfer of pp65-specific T-cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360–4367.CrossRefGoogle ScholarPubMed

Peggs, KS, Thomson, K, Samuel, E, et al. Directly selected cytomegalovirus-reactive donor T-cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis. 2011;52(1):49–57.CrossRefGoogle ScholarPubMed

Uhlin, M, Okas, M, Gertow, J, Uzunel, M, Brismar, TB, Mattsson, J. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother. 2010;59(3):473–477.CrossRefGoogle ScholarPubMed

Moosmann, A, Bigalke, I, Tischer, J, et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010;115(14):2960–2970.CrossRefGoogle ScholarPubMed

Uhlin, M, Gertow, J, Uzunel, M, et al. Rapid salvage treatment with virus-specific T-cells for therapy-resistant disease. Clin Infect Dis. 2012;55(8):1064–1073.CrossRefGoogle ScholarPubMed

Leen, AM, Christin, A, Myers, GD, et al. Cytotoxic T lymphocyte therapy with donor T-cells prevents and treats adenovirus and Epstein–Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114(19):4283–4292.CrossRefGoogle ScholarPubMed

Micklethwaite, KP, Clancy, L, Sandher, U, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood. 2008;112(10):3974–3981.CrossRefGoogle ScholarPubMed

Feuchtinger, T, Matthes-Martin, S, Richard, C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134(1):64–76.CrossRefGoogle ScholarPubMed

Qasim, W, Derniame, S, Gilmour, K, et al. Third-party virus-specific T-cells eradicate adenoviraemia but trigger bystander graft-versus-host disease. Br J Haematol. 2011;154(1):150–153.CrossRefGoogle ScholarPubMed

Blyth, E, Clancy, L, Simms, R, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013;121(18):3745–3758.CrossRefGoogle ScholarPubMed

Vera, JF, Brenner, LJ, Gerdemann, U, et al. Accelerated production of antigen-specific T-cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010;33(3):305–315.CrossRefGoogle Scholar

Papadopoulou, A, Gerdemann, U, Katari, UL, et al. Activity of broad-spectrum T cells as treatment for Adv, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra283.CrossRefGoogle ScholarPubMed

Lam, S, Bollard, C. T-cell therapies for HIV. Immunotherapy. 2013;5(4):407–414.CrossRefGoogle Scholar

Lieberman, J, Skolnik, PR, Parkerson, GR, 3rd, et al. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood. 1997;90(6):2196–2206.Google ScholarPubMed

Deeks, SG, Wagner, B, Anton, PA, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther. 2002;5(6):788–797.CrossRefGoogle ScholarPubMed

Mitsuyasu, RT, Anton, PA, Deeks, SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T-cells in human immunodeficiency virus-infected subjects. Blood. 2000;96(3):785–793.Google ScholarPubMed

Tebas, P, Stein, D, Binder-Scholl, G, et al. Antiviral effects of autologous CD4 T-cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood. 2013;121(9):1524–1533.CrossRefGoogle Scholar

Tebas, P, Stein, D, Tang, WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. New Engl J Med. 2014;370(10):901–910.CrossRefGoogle Scholar

Didigu, CA, Wilen, CB, Wang, J, et al. Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T-cells from HIV-1 infection. Blood. 2014;123(1):61–69.CrossRefGoogle ScholarPubMed

Balduzzi, A, Lucchini, G, Hirsch, HH, et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant. 2011;46(7):987–992.CrossRefGoogle Scholar

Ramos, CA, Narala, N, Vyas, GM, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother. 2013;36(1):66–76.CrossRefGoogle ScholarPubMed

Cruz, CR, Hanley, PJ, Liu, H, et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010;12(6):743–749.CrossRefGoogle ScholarPubMed

Haque, T, Taylor, C, Wilkie, GM, et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T-cells. Transplantation. 2001;72(8):1399–1402.CrossRefGoogle Scholar

Haque, T, Wilkie, GM, Taylor, C, et al. Treatment of Epstein–Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T-cells. Lancet. 2002;360(9331):436–442.CrossRefGoogle ScholarPubMed

Haque, T, Wilkie, GM, Jones, MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110(4):1123–1131.CrossRefGoogle Scholar

Barker, JN, Doubrovina, E, Sauter, C, et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood. 2010;116(23):5045–5049.CrossRefGoogle ScholarPubMed

Leen, AM, Bollard, CM, Mendizabal, AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113–5123.CrossRefGoogle ScholarPubMed

Wy Ip, W, Qasim, W. Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation. Adv Hematol. 2013;2013:176418.CrossRefGoogle ScholarPubMed

Schub, A, Schuster, IG, Hammerschmidt, W, Moosmann, A. CMV-specific TCR-transgenic T-cells for immunotherapy. J Immunol. 2009;183(10):6819–6830.CrossRefGoogle ScholarPubMed

Xue, SA, Gao, L, Ahmadi, M, et al. Human MHC Class I-restricted high avidity CD4 T-cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology. 2013;2(1):e22590.CrossRefGoogle ScholarPubMed

Frumento, G, Zheng, Y, Aubert, G, et al. Cord blood T cells retain early differentiation phenotype suitable for immunotherapy after TCR gene transfer to confer EBV specificity. Am J Transplant. 2013;13(1):45–55.CrossRefGoogle ScholarPubMed

Basso, S, Zecca, M, Calafiore, L, et al. Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein–Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient. Pediatr Transplant. 2013;17(7):E168–173.Google Scholar

Haque, T, Amlot, PL, Helling, N, et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol. 1998;160(12):6204–6209.Google ScholarPubMed

Savoldo, B, Goss, J, Liu, Z, et al. Generation of autologous Epstein–Barr virus-specific cytotoxic T-cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 2001;72(6):1078–1086.CrossRefGoogle ScholarPubMed

Romani, L. Immunity to fungal infections. Nat Rev Immunol. 2004;4(1):1–23.CrossRefGoogle ScholarPubMed

Groll, AH, McNeil, Grist L. Current challenges in the diagnosis and management of invasive fungal infections: report from the 15th International Symposium on Infections in the Immunocompromised Host: Thessaloniki, Greece, 22–25 June 2008. Int J Antimicrob Agents. 2009;33(2):101–104.CrossRefGoogle ScholarPubMed

Milner, JD, Holland, SM. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Nat Rev Immunol. 2013;13(9):635–648.CrossRefGoogle ScholarPubMed

Kim, CJ, McKinnon, LR, Kovacs, C, et al. Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol. 2013;191(5):2164–2173.CrossRefGoogle Scholar

Cruz, CR, Lam, S, Hanley, PJ, et al. Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin Exp Immunol. 2013;174(1):89–96.CrossRefGoogle ScholarPubMed

Beck, O, Topp, MS, Koehl, U, et al. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood. 2006;107(6):2562–2569.CrossRefGoogle ScholarPubMed

Tramsen, L, Schmidt, S, Boenig, H, et al. Clinical-scale generation of multi-specific anti-fungal T cells targeting Candida, Aspergillus and mucormycetes. Cytotherapy. 2013;15(3):344–351.CrossRefGoogle ScholarPubMed

Khanna, N, Stuehler, C, Conrad, B, et al. Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood. 2011;118(4):1121–1131.CrossRefGoogle ScholarPubMed

Gomez, MJ, Maras, B, Barca, A, La Valle, R, Barra, D, Cassone, A. Biochemical and immunological characterization of MP65, a major mannoprotein antigen of the opportunistic human pathogen Candida albicans. Infect Immun. 2000;68(2):694–701.CrossRefGoogle Scholar

Jolink, H, Meijssen, IC, Hagedoorn, RS, et al. Characterization of the T-cell-mediated immune response against the Aspergillus fumigatus proteins Crf1 and catalase 1 in healthy individuals. J Infect Dis. 2013;208(5):847–856.CrossRefGoogle ScholarPubMed

Schmidt, S, Tramsen, L, Perkhofer, S, et al. Characterization of the cellular immune responses to Rhizopus oryzae with potential impact on immunotherapeutic strategies in hematopoietic stem cell transplantation. J Infect Dis. 2012;206(1):135–139.CrossRefGoogle ScholarPubMed

Tramsen, L, Beck, O, Schuster, FR, et al. Generation and characterization of anti-Candida T-cells as potential immunotherapy in patients with Candida infection after allogeneic hematopoietic stem-cell transplant. J Infect Dis. 2007;196(3):485–492.CrossRefGoogle ScholarPubMed

Goodridge, HS, Wolf, AJ, Underhill, DM. Beta-glucan recognition by the innate immune system. Immunol Rev. 2009;230(1):38–50.CrossRefGoogle ScholarPubMed

Perruccio, K, Tosti, A, Burchielli, E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106(13):4397–4406.CrossRefGoogle ScholarPubMed

De Angelis, B, Dotti, G, Quintarelli, C, et al. Generation of Epstein–Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009;114(23):4784–4791.CrossRefGoogle Scholar

Brewin, J, Mancao, C, Straathof, K, et al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood. 2009;114(23):4792–4803.CrossRefGoogle ScholarPubMed

Vera, JF, Brenner, LJ, Gerdemann, U, et al. Accelerated production of antigen-specific T-cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010;33(3):305–315.CrossRefGoogle Scholar

Gattinoni, L, Lugli, E, Ji, Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290–1297.CrossRefGoogle ScholarPubMed

Williams, DM, Weiner, MH, Drutz, DJ. Immunologic studies of disseminated infection with Aspergillus fumigatus in the nude mouse. J Infect Dis. 1981;143(5):726–733.CrossRefGoogle ScholarPubMed

Holding, KJ, Dworkin, MS, Wan, PC, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. Clin Infect Dis. 2000;31(5):1253–1257.CrossRefGoogle ScholarPubMed

Zelante, T, De Luca, A, Bonifazi, P, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol. 2007;37(10):2695–2706.CrossRefGoogle ScholarPubMed

Werner, JL, Gessner, MA, Lilly, LM, et al. Neutrophils produce interleukin 17A (IL-17A) in a dectin-1- and IL-23-dependent manner during invasive fungal infection. Infect Immun. 2011;79(10):3966–3977.CrossRefGoogle Scholar

Marr, KA, Carter, RA, Boeckh, M, Martin, P, Corey, L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–4366.CrossRefGoogle ScholarPubMed

Zimmerli, W, Zarth, A, Gratwohl, A, Speck, B. Neutrophil function and pyogenic infections in bone marrow transplant recipients. Blood. 1991;77(2):393–399.Google ScholarPubMed

Cobbold, M, Khan, N, Pourgheysari, B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202(3):379–386.CrossRefGoogle ScholarPubMed

Peggs, KS, Thomson, K, Samuel, E, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis. 2011;52(1):49–57.CrossRefGoogle ScholarPubMed

Uhlin, M, Okas, M, Gertow, J, Uzunel, M, Brismar, TB, Mattsson, J. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother. 2010;59(3):473–477.CrossRefGoogle Scholar

Qasim, W, Derniame, S, Gilmour, K, et al. Third-party virus-specific T-cells eradicate adenoviraemia but trigger bystander graft-versus-host disease. Br J Haematol. 2011;154(1):150–153.CrossRefGoogle ScholarPubMed

Feuchtinger, T, Matthes-Martin, S, Richard, C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134(1):64–76.CrossRefGoogle ScholarPubMed

Balduzzi, A, Lucchini, G, Hirsch, HH, et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant. 2011;46(7):987–992.CrossRefGoogle Scholar

Uhlin, M, Gertow, J, Uzunel, M, et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis. 2012;55(8):1064–1073.CrossRefGoogle ScholarPubMed

Leen, AM, Myers, GD, Sili, U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160–1166.CrossRefGoogle ScholarPubMed

Gerdemann, U, Katari, UL, Papadopoulou, A, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T-cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013;21(11):2113–2121.CrossRefGoogle ScholarPubMed

Tramsen, L, Koehl, U, Tonn, T, et al. Clinical-scale generation of human anti-Aspergillus T-cells for adoptive immunotherapy. Bone Marrow Transplant. 2009;43(1):13–19.CrossRefGoogle ScholarPubMed

Gaundar, SS, Clancy, L, Blyth, E, Meyer, W, Gottlieb, DJ. Robust polyfunctional T-helper 1 responses to multiple fungal antigens from a cell population generated using an environmental strain of Aspergillus fumigatus. Cytotherapy. 2012;14(9):1119–1130.CrossRefGoogle ScholarPubMed

Stuehler, C, Khanna, N, Bozza, S, et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood. 2011;117(22):5881–5891.CrossRefGoogle ScholarPubMed

Jolink, H, Meijssen, IC, Hagedoorn, RS, et al. Characterization of the T-cell-mediated immune response against the Aspergillus fumigatus proteins Crf1 and catalase 1 in healthy individuals. J Infect Dis. 2013;208(5):847–856.CrossRefGoogle ScholarPubMed

Feng, CG, Britton, WJ. CD4+ and CD8+ T cells mediate adoptive immunity to aerosol infection of Mycobacterium bovis bacillus Calmette-Guerin. J Infect Dis. 2000;181(5):1846–1849.CrossRefGoogle ScholarPubMed

Stemberger, C, Graef, P, Odendahl, M, et al. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood. 2014;124(4):628–637.CrossRefGoogle ScholarPubMed

Bhadra, R, Cobb, DA, Khan, IA. Donor CD8+ T cells prevent Toxoplasma gondii de-encystation but fail to rescue the exhausted endogenous CD8+ T cell population. Infect Immun. 2013;81(9):3414–3425.CrossRefGoogle ScholarPubMed

Polley, R, Stager, S, Prickett, S, et al. Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen. Infect Immun. 2006;74(1):773–776.CrossRefGoogle ScholarPubMed

Naik, S, Nicholas, SK, Martinez, CA, et al., Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016;137(5):1498–505.CrossRefGoogle ScholarPubMed

Henrickson, KJ. Parainfluenza viruses. Clin Microbiol Rev. 2003;16(2):242–64.CrossRefGoogle ScholarPubMed

Nichols, WG, Corey, L, Gooley, T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood. 2001;98(3):573–8.CrossRefGoogle ScholarPubMed

McLaughlin, L, Lang, H, Williams, E, et al. Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes. Cytotherapy. 2016;18(12):1515–24.CrossRefGoogle ScholarPubMed

Barrett, AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol. 2008;142(6):877–88.CrossRefGoogle ScholarPubMed

Gale, RP, Horowitz, MM, Ash, RC, Champlin, RE, Goldman, JM, Rimm, AA, Ringdén, O, Stone, JA, Bortin, MM.Identical-twin bone marrow transplants for leukemia. Ann Intern Med. 1994;120(8):646–52.CrossRefGoogle ScholarPubMed

Barrett, AJ, Ringdén, O, Zhang, MJ, Bashey, A, Cahn, JY, Cairo, MS, Gale, RP, Gratwohl, A, Locatelli, F, Martino, R, Schultz, KR, Tiberghien, P. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood. 2000;95(11):3323–7.Google ScholarPubMed

Ringdén, O, Pavletic, SZ, Anasetti, C, Barrett, AJ, Wang, T, Wang, D, Antin, JH, Di Bartolomeo, P, Bolwell, BJ, Bredeson, C, Cairo, MS, Gale, RP, Gupta, V, Hahn, T, Hale, GA, Halter, J, Jagasia, M, Litzow, MR, Locatelli, F, Marks, DI, McCarthy, PL, Cowan, MJ, Petersdorf, EW, Russell, JA, Schiller, GJ, Schouten, H, Spellman, S.The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009;113(13):3110–8.CrossRefGoogle Scholar

Vago, L, Toffalori, C, Ciceri, F, Fleischhauer, K. Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia. Semin Oncol. 2012;39(6):707–15.CrossRefGoogle ScholarPubMed

Weisdorf, D, Which donor or graft source should you choose for the strongest GVL? Is there really any difference. Best Pract Res Clin Haematol 2013; 26: 293–6.CrossRefGoogle ScholarPubMed

Pegram, HJ, Ritchie, DS, Smyth, MJ, Wiernik, A, Prince, HM, Darcy, PK, Kershaw, MH. Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leuk Res. 2011;35(1):14–21.CrossRefGoogle ScholarPubMed

Moretta, L, Locatelli, F, Pende, D, Marcenaro, E, Mingari, MC, Moretta, A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 2011;117(3):764–71.CrossRefGoogle ScholarPubMed

Davies, JO, Stringaris, K, Barrett, JA, Rezvani, K. Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. Cytotherapy. 2014;May 20. [Epub ahead of print]

Reshef, R, Hexner, EO, Frey, NV, Stadtmauer, EA, Luger, SM, Mangan, JK, Gill, SI, Vassilev, P, Lafferty, KA, Smith, J, Van Deerlin, VM, Mick, R4, Porter, DL. Early donor chimerism levels predict relapse and survival after allogeneic stem-cell transplantation with reduced intensity conditioning. Biol Blood Marrow Transplant. 2014; Jul 9. [Epub ahead of print]

Reisner, Y, Gur, H, Reich-Zeliger, S, Martelli, MF, Bachar-Lustig, E. Hematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells. Ann N Y Acad Sci. 2005;1044:70–83.CrossRefGoogle ScholarPubMed

Singh, AK, Savani, BN, Albert, PS, Barrett, AJ. Efficacy of CD34+ stem cell dose in patients undergoing allogeneic peripheral blood stem cell transplantation after total body irradiation.Biol Blood Marrow Transplant. 2007;13(3):339–44.CrossRefGoogle ScholarPubMed

Ringdén, O, Barrett, AJ, Zhang, MJ, Loberiza, FR, Bolwell, BJ, Cairo, MS, Gale, RP, Hale, GA, Litzow, MR, Martino, R, Russell, JA, Tiberghien, P, Urbano-Ispizua, A, Horowitz, MM. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol. 2003;121(6):874–85.CrossRefGoogle ScholarPubMed

Chang, YJ, Weng, CL, Sun, LX, Zhao, YT. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials. Ann Hematol. 2012;91(3):427–37.CrossRefGoogle ScholarPubMed

Norkin, M, Uberti, JP, Schiffer, CA. Very late recurrences of leukemia: why does leukemia awake after many years of dormancy? Leuk Res. 2011;35(2):139–44.CrossRefGoogle ScholarPubMed

Bacigalupo, A, Vitale, V, Corvo, R, Barra, S, Lamparelli, T, Gualandi, F, Mordini, N, Berisso, G, Bregante, S, Raiola, AM, Van Lint, MT, Frassoni, F. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol. 2000;108:99–104.CrossRefGoogle ScholarPubMed

Locatelli, F, Zecca, M, Rondelli, R, Bonetti, F, Dini, G, Prete, A, Messina, C, Uderzo, C, Ripaldi, M, Porta, F, Giorgiani, G, Giraldi, E, Pession, A. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood. 2000;95:1572–9.Google ScholarPubMed